Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC-Reference-Cited by-同舟云学术

Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC

Published:2021-09-22 Issue:6 Volume:27 Page:967-973
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Miesbach Wolfgang¹^ORCID,Chowdary Pratima²^ORCID,Coppens Michiel³,Hart Daniel P.⁴^ORCID,Jimenez‐Yuste Victor⁵^ORCID,Klamroth Robert⁶^ORCID,Makris Michael⁷^ORCID,Noone Declan⁸,Peyvandi Flora⁹¹⁰^ORCID

Affiliation:

1. Medical Clinic 2 Institute of Transfusion Medicine University Hospital Frankfurt Frankfurt Germany

2. Katharine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital London UK

3. Department of Vascular Medicine Haemophilia Treatment Centre Amsterdam Cardiovascular Sciences Amsterdam University Medical Centres University of Amsterdam Amsterdam The Netherlands

4. The Royal London Hospital Haemophilia Centre Barts and The London School of Medicine and Dentistry, QMUL London UK

5. Hematology Department Hospital Universitario La Paz, Autonoma University Madrid Spain

6. Department for Internal Medicine and Vascular Medicine Haemophilia Treatment Centre Vivantes Hospital im Friedrichshain Berlin Germany

7. Department of Infection Immunity and Cardiovascular Disease University of Sheffield, Sheffield UK

8. European Haemophilia Consortium Brussels Belgium

9. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre and Fondazione Luigi Villa Milan Italy

10. Università degli Studi di Milano Department of Pathophysiology and Transplantation Milan Italy

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14420

Reference18 articles.

1. Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies

2. WFH Guidelines for the Management of Hemophilia, 3rd edition

3. The methodology for defining the European standards for the certification of Haemophilia Centres in Europe;Candura F;Blood transfusion = Trasfusione del sangue,2014

4. www.euhass.org

5. Delivering on the promise of gene therapy for haemophilia;Pipe SW;Haemophilia,2020

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strengthening health systems for access to gene therapy in rare genetic disorders;Molecular Therapy - Methods & Clinical Development;2024-06

2. A 360-degree perspective on adeno-associated virus (AAV)-based gene therapy for haemophilia: Insights from the physician, the nurse and the patient;Orphanet Journal of Rare Diseases;2024-05-13

3. Hämophilie-Behandlung in Österreich;Wiener klinische Wochenschrift;2024-05

4. Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene Therapy;Journal of Thrombosis and Haemostasis;2024-05

5. Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives;Seminars in Thrombosis and Hemostasis;2024-04-08